OncoSec Medical Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0002
- Today's High:
- $0.0002
- Open Price:
- $0.0002
- 52W Low:
- $0.0002
- 52W High:
- $13.6158
- Prev. Close:
- $0.0002
- Volume:
- 158
Company Statistics
- Market Cap.:
- $1.65 million
- Book Value:
- -1.847
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -92.84%
- Return on Equity TTM:
- -410.17%
Company Profile
OncoSec Medical Inc had its IPO on 2011-03-31 under the ticker symbol ONCS.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. OncoSec Medical Inc has a staff strength of 40 employees.
Stock update
Shares of OncoSec Medical Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a 0% increase from the previous day's closing price.
A total volume of 158 shares were traded at the close of the day’s session.
In the last one week, shares of OncoSec Medical Inc have slipped by -99.12%.
OncoSec Medical Inc's Key Ratios
OncoSec Medical Inc has a market cap of $1.65 million, indicating a price to book ratio of 0.7817 and a price to sales ratio of 0.
In the last 12-months OncoSec Medical Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32398344. The EBITDA ratio measures OncoSec Medical Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, OncoSec Medical Inc’s operating margin was 0% while its return on assets stood at -92.84% with a return of equity of -410.17%.
In Q0.33333333333333, OncoSec Medical Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
OncoSec Medical Inc’s PE and PEG Ratio
- Forward PE
- 8.6655
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-20.31 per share while it has a forward price to earnings multiple of 8.6655 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into OncoSec Medical Inc’s profitability.
OncoSec Medical Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0369. Its price to sales ratio in the trailing 12-months stood at 0.
OncoSec Medical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.87 million
- Total Liabilities
- $7.23 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $15955
- Dividend Payout Ratio
- 0%
OncoSec Medical Inc ended 2024 with $8.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.87 million while shareholder equity stood at $-5486461.00.
OncoSec Medical Inc ended 2024 with $0 in deferred long-term liabilities, $7.23 million in other current liabilities, 297.00 in common stock, $-300879943.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.68 million and cash and short-term investments were $3.68 million. The company’s total short-term debt was $1,337,653 while long-term debt stood at $1.91 million.
OncoSec Medical Inc’s total current assets stands at $6.44 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, OncoSec Medical Inc's operating cash flow was $0 while its capital expenditure stood at $15955.
Comparatively, OncoSec Medical Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $13.6158
- 52-Week Low
- $0.0002
- Analyst Target Price
- $110
OncoSec Medical Inc stock is currently trading at $0 per share. It touched a 52-week high of $13.6158 and a 52-week low of $13.6158. Analysts tracking the stock have a 12-month average target price of $110.
Its 50-day moving average was $0.07 and 200-day moving average was $1.35 The short ratio stood at 0.34 indicating a short percent outstanding of 0%.
Around 2801.4% of the company’s stock are held by insiders while 583.1% are held by institutions.
Frequently Asked Questions About OncoSec Medical Inc
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University’s Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.